Linkage of Cancer and Lupus in Gliomas Patients
25 mars 2024 08h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA...
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
28 nov. 2023 07h10 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its Chief Executive Officer (“CEO”),...
Oncotelic Announces the launch of PDAO token
17 janv. 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Oncotelic Announces Formation of Animal Health Division
06 oct. 2022 08h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), directly and / or through its wholly owned subsidiaries...
Oncotelic Presenting at BiotechGate Digital Partnering
24 févr. 2022 08h01 HE
|
Oncotelic Therapeutics, Inc.
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
22 déc. 2021 07h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01 mars 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT
25 janv. 2021 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
14 oct. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
OT-101 PRESENTATION AT PHARMA FORUM 2020
21 sept. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that on...